The impact of biologics in surgical outcomes in ulcerative colitis
作者： Marjorie C. Argollo , Paulo Gustavo Kotze , Antonino Spinelli , Tarcia N.F. Gomes , Silvio Danese
DOI: 10.1016/J.BPG.2018.05.014
关键词:
摘要: Ulcerative Colitis (UC) is an immune mediated condition characterized by inflammation of colonic mucosa, associated with progressive damage the colon and possible complications, such as hemorrhage, perforation cancer. It strongly advocated a treat to target approach in patients UC consisting early aggressive inflammatory control. Some can require colectomy for medically refractory disease or neoplasia. Even though first line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) improvement some patients, others do not respond at lose response over time. Novel drugs different pathways have been studied UC, however, it remains unclear whether surgical rates reduced biological era. Controversy also exists if agents impair postoperative complication UC. The aim this review describe all relevant data available briefly summarize real impact biologics outcomes ulcerative colitis.
elsevier.com
sci-hub.se 参考文章(84)
A. Dignass, J. Preiß, D. Aust, F. Autschbach, A. Ballauff, G. Barretton, B. Bokemeyer, S. Fichtner-Feigl, S. Hagel, K. Herrlinger, G. Jantschek, A. Kroesen, W. Kruis, T. Kucharzik, J. Langhorst, M. Reinshagen, G. Rogler, D. Schleiermacher, C. Schmidt, S. Schreiber, H. Schulze, E. Stange, M. Zeitz, J. Hoffmann, A. Stallmach, [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. Zeitschrift Fur Gastroenterologie. ,vol. 49, pp. 1276- 1341 ,(2011) , 10.1055/S-0031-1281666
M Chaparro, P Burgueño, E Iglesias, J Panés, F Muñoz, G Bastida, L Castro, C Jiménez, JL Mendoza, M Barreiro‐de Acosta, S Gomez Senent, F Gomollón, X Calvet, E García‐Planella, M Gómez, V Hernández, J Hinojosa, M Mañosa, O Perez Nyssen, JP Gisbert, None, Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study Alimentary Pharmacology & Therapeutics. ,vol. 35, pp. 275- 283 ,(2012) , 10.1111/J.1365-2036.2011.04934.X
A. KOHN, M. DAPERNO, A. ARMUZZI, M. CAPPELLO, L. BIANCONE, A. ORLANDO, A. VISCIDO, V. ANNESE, G. RIEGLER, G. MEUCCI, M. MARROLLO, R. SOSTEGNI, A. GASBARRINI, S. PERALTA, C. PRANTERA, Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up Alimentary Pharmacology & Therapeutics. ,vol. 26, pp. 747- 756 ,(2007) , 10.1111/J.1365-2036.2007.03415.X
Florian Kühn, Ernst Klar, Surgical Principles in the Treatment of Ulcerative Colitis Visceral medicine. ,vol. 31, pp. 246- 250 ,(2015) , 10.1159/000438894
Saloomeh Sahami, Christianne J. Buskens, Tonia Young Fadok, Pieter J. Tanis, Anthony de Buck van Overstraeten, Albert M. Wolthuis, Willem A. Bemelman, André D’Hoore, Defunctioning Ileostomy is not Associated with Reduced Leakage in Proctocolectomy and Ileal Pouch Anastomosis Surgeries for IBD Journal of Crohns & Colitis. ,vol. 10, pp. 779- 785 ,(2016) , 10.1093/ECCO-JCC/JJV201
M. P. Powar, P. Martin, A. R. Croft, A. Walsh, D. Petersen, A. R. L. Stevenson, J. W. Lumley, R. W. Stitz, G. L. Radford-Smith, D. A. Clark, Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy. Colorectal Disease. ,vol. 15, pp. 374- 379 ,(2013) , 10.1111/J.1463-1318.2012.03188.X
M. Sjöberg, A. Magnuson, J. Björk, C. Benoni, S. Almer, I. Friis-Liby, E. Hertervig, M. Olsson, P. Karlén, A. Eriksson, G. Midhagen, M. Carlson, A. Lapidus, J. Halfvarson, C. Tysk, , Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Alimentary Pharmacology & Therapeutics. ,vol. 38, pp. 377- 387 ,(2013) , 10.1111/APT.12387
William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu, Kevin Horgan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands, Jean Frédéric Colombel, Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab Gastroenterology. ,vol. 137, pp. 1250- 1260 ,(2009) , 10.1053/J.GASTRO.2009.06.061
William J Sandborn, Brian G Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J Adedokun, Cynthia Guzzo, Jean-Frederic Colombel, Walter Reinisch, Peter R Gibson, Judith Collins, Gunnar Järnerot, Toshifumi Hibi, Paul Rutgeerts, PURSUIT-SC Study Group, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. ,vol. 146, pp. 85- 95 ,(2014) , 10.1053/J.GASTRO.2013.05.048
Oren Shibolet, Infliximab in ulcerative colitis. Biologics: Targets & Therapy. ,vol. 2, pp. 379- 388 ,(2008) , 10.2147/BTT.S2249